Ebos Group Limited · NZX:EBO
Ebos — Shareholder Meeting (October 2025)
50 slides from Ebos's shareholder meeting presentation, Oct 29, 2025
Slide 1: EBOS Group Limited 2025 Annual Meeting
29 October 2025 NZX/ASX Code: EBO EBOS GROUP LIMITED 2025 ANNUAL MEETING Please see attached the Chair's speech, CEO's speech and presentation materials for the Annual Meeting of shareholders to be held today. For personal use only Authorised for lodgement with NZX and ASX by the Board of EBOS Group
Slide 2: Chair's Address to Shareholders
Chair’s Address to Shareholders I am pleased to be here today to update you on EBOS Group’s 2025 financial year performance, which highlights our continued track record of strong revenue growth and operational excellence. I would like to start with a video that captures the key highlights and activi
Slide 3: Chair's Address (continued)
Having delivered a solid result in FY25, the current financial year is set to be a year of transition, as we manage the near-term macro pressures. We will focus on positioning our business for the future by making considered and disciplined investments and achieving operational efficiencies from our
Slide 4: Chair's Address (continued)
consultation with key stakeholders and will continue to enhance our health and safety culture. We also continued to support various initiatives and organisations aligned with our purpose of advancing opportunities to enrich lives. This included strategic partnerships with organisations such as Ovari
Slide 5: CEO's Address to Shareholders
CEO’s Address to Shareholders Good afternoon everyone and thank you for joining us today. It’s a privilege to be here with you, and I’d like to begin by acknowledging the support of our shareholders, our Board, and the broader EBOS team. Since stepping into the role, I’ve had the opportunity to visi
Slide 6: CEO's Address: FY26 guidance
Looking ahead to FY26, today, we reaffirm our existing FY26 guidance that was provided to the market in August. The existing guidance has us targeting underlying Group EBITDA of between $615 to $635 million. This represents approximately 7% growth at the midpoint. The guidance provided to the market
Slide 7: CEO's Address: Government funding and Kemps Creek
The Australian Government recognises the essential role of pharmacy in the healthcare sector. In 2024 there were two landmark agreements signed. The first Pharmacy Wholesale Agreement, which increases the CSO funding pool and improves the sustainability of funding for wholesalers, and also the 8th C
Slide 8: CEO's Address: DC renewal program
We’ve streamlined operations across sites, removed duplication, and improved scalability. This includes consolidating our New Zealand footprint through ProPharma and Onelink and enhancing our hospital distribution capabilities. From FY27 onwards, we expect to see a step-down in our annual capex – ap
Slide 9: CEO's Address: TWC and myTWC
Looking ahead to FY26, we’re focused on driving momentum through continued network expansion, launching new TWC-branded products, and accelerating adoption of our digital platforms. And in FY27 and beyond, we see significant opportunity to unlock new growth horizons particularly through our CareClin
Slide 10: CEO's Address: Medical Technology and Animal Care
We’re investing in new product development across emerging therapy areas and expanding our allograft solutions. In short, Medical Technology is evolving from a high-performing segment into a core growth driver for EBOS. It combines strong market fundamentals, strategic execution, and a disciplined a
Slide 11: CEO's Address: Investment proposition
To conclude today’s presentation, I want to reaffirm the EBOS investment proposition and share what energises me about leading this exceptional business. Healthcare and animal care continue to experience sustained increases in consumer and institutional spend, driven by demographic shifts, innovatio
Slide 12: For personal use only
For personal use only
Slide 13: Disclaimer
DISCLAIMER The information in this presentation was prepared by EBOS Group Limited (“EBOS” or the “Group”) with due care and attention. However, the information is supplied in summary form and is therefore For personal use only not necessarily complete, and, to the extent permitted by law, no repres
Slide 14: For personal use only
For personal use only
Slide 15: How to participate in virtual/hybrid meetings and ask a question
HOW TO PARTICIPATE IN VIRTUAL/ HYBRID MEETINGS AND ASK A QUESTION For personal use only 4
Slide 16: How to participate in virtual/hybrid meetings and vote
HOW TO PARTICIPATE IN VIRTUAL/ HYBRID MEETINGS AND VOTE For personal use only 5
Slide 17: Introducing our Board
Ajuo asn jeuosi Introducing our Board
Slide 18: Board of Directors
For personal use only 7 BOARD OF DIRECTORS
Slide 19: Agenda
AGENDA For personal use only 01 Presentation: Elizabeth Coutts, Chair 02 Presentation: Adam Hall, CEO 03 Business of meeting 04 Conclusion 8
Slide 20: Presentation: Elizabeth Coutts, Chair
Presentation Elizabeth Coutts, Chair
Slide 21: Video placeholder
To be updated – placeholder from 2024 For personal use only VIDEO TO BE UPDATED TO 2025 10
Slide 22: Well Positioned Portfolio
WELL POSITIONED PORTFOLIO Portfolio positioned well for long-term growth For personal use only • A leading pharmaceutical wholesaler in Australia and the largest in New Zealand • TerryWhite Chemmart network is Australia’s largest health services focussed community pharmacy network • One of ANZ’s lar
Slide 23: Setting the Stage
SETTING THE STAGE For personal use only 1 2 3 FY26: Positioning FY25: A solid result FY27+: Sustainable growth for the future 12
Slide 24: Consistent Earnings Growth and Shareholder Returns Over the Long Term
EBOS HAS DELIVERED CONSISTENT EARNINGS GROWTH AND SHAREHOLDER RETURNS OVER THE LONG TERM For personal use only Underlying EBITDA1 ($m) Guidance: • Double-digit earnings 582 624 $615-635m 10-year CAGR2 585 growth 437 336 367 • Positive macro trends 228 250 262 ~12% and leading positions 208 CAGR enab
Slide 25: Environmental, Social, Governance
ENVIRONMENTAL, SOCIAL, GOVERNANCE We recognise our responsibility as a provider of essential network infrastructure, products, and services to improving both human and animal health outcomes. For personal use only Our sustainability pillars ESG highlights • Progressed toward generating renewable ele
Slide 26: CEO Succession and Board Renewal
CEO SUCCESSION AND BOARD RENEWAL CEO Directors For personal use only • Coline McConville appointed • Adam Hall commenced as CEO 1 February 2025 1 July 2025 Board Renewal • Five new Directors since July 2021 • In making any appointment to the Board, the directors have regard to its skills matrix whic
Slide 27: Dividend
DIVIDEND Final dividend For personal use only • EBOS’ Directors announced a final FY25 dividend of NZ 61.5 cents per share. • The final dividend was fully franked for Australian taxation purposes and imputed to 25% for New Zealand taxation purposes. Full year • Taking the full-year dividend to NZ 118
Slide 28: Presentation: Adam Hall, CEO
Presentation Adam Hall, CEO
Slide 29: Delivering Sustainable Shareholder Returns
DELIVERING SUSTAINABLE SHAREHOLDER RETURNS 1 2 3 FY25: A solid result FY26: Positioning for the future FY27+: Sustainable growth For personal use only • 7.5% EBITDA growth1 • Targeting Group Underlying EBITDA of $615 3A Symbion & Healthcare Distribution: Business to benefit from scale, service, – 63
Slide 30: FY25 Result Consistent with Guidance
1 FY25 RESULT CONSISTENT WITH GUIDANCE, REFLECTING SOLID UNDERLYING EBITDA GROWTH1 OF 7.5% For personal use only Revenue Underlying EBITDA • Organic growth supported by new pharmacy wholesale customers, growth in Southeast Asia within Medical $12,267m $585m Technology, and from TWC franchise network
Slide 31: FY26 Outlook: Strategic Growth and Key Milestones Ahead
2 FY26 OUTLOOK: STRATEGIC GROWTH AND KEY MILESTONES AHEAD • EBOS reaffirms its guidance for FY26, targeting Group Underlying EBITDA of between $615 - 635m, reflecting ~7% midpoint growth. All other outlook statements are unchanged as noted in the FY25 results presentation1 For personal use only - We
Slide 32: Symbion Healthcare & Distribution
3A SYMBION HEALTHCARE & DISTRIBUTION BUSINESS TO BENEFIT FROM SCALE, CSO LEVERAGE AND SHARE CAPTURE FY25: Solid replacement FY26: Final year of FY27+: Operational and financial leverage For personal use only of earnings investment Pharmacy Wholesale • New customer growth • Commissioning of new Symbi
Slide 33: Additional Government Industry Funding for Pharmacy Wholesalers
3A RECOGNISING THE ESSENTIAL ROLE OF PHARMACY WHOLESALERS, THE AUSTRALIAN GOVERNMENT HAS DELIVERED ADDITIONAL INDUSTRY FUNDING Key funding changes: Benefit to EBOS For personal use only 1. Eighth Community Pharmacy Agreement • Community pharmacy customers well supported by stable • Negotiated betwee
Slide 34: DC Renewal: Building Capacity for Future Growth
3A DC RENEWAL: BUILDING CAPACITY FOR FUTURE GROWTH AND DRIVING EFFICIENCY Strategic pillars 2023 2024 2025 2026 For personal use only Growth • Expanding capacity to Contract Logistics: Contract Logistics: Contract Logistics: capture high-value markets Sydney Auckland Perth • National footprint Estab
Slide 35: Expanding Our Contract Logistics Footprint
3A EXPANDING OUR CONTRACT LOGISTICS FOOTPRINT Original Sydney site Second Sydney site New Perth site For personal use only • Opened 2018 • Opened 2023 • Opening 2026 • Fully utilised • ~70% utilised • Facility to provide national footprint Distribution centres by t ype: Contract logistics Symbion •
Slide 36: Growing a Leading Health Services Focussed Retail Pharmacy Network
3B GROWING A LEADING HEALTH SERVICES FOCUSSED RETAIL PHARMACY NETWORK FOR TOMORROW FY25: Building scale & FY26: Driving momentum FY27+: Unlocking new growth horizons For personal use only reach Retail Pharmacy • Added 34 net new stores to TWC • Ongoing network expansion • Scope of service expansion:
Slide 37: myTWC: Powering Digital Growth in Pharmacy
3B myTWC: POWERING DIGITAL GROWTH IN PHARMACY 1 2 3 For personal use only Strategic importance: Performance highlights: What’s next: • A fully-integrated platform that • ~800k registered users: growing • Unlock pharmacist productivity by connects customers, pharmacists and 30% YoY digitising workflo
Slide 38: Sustained Growth Runway in Medical Technology
3C SUSTAINED GROWTH RUNWAY IN MEDICAL TECHNOLOGY FY25: Best performer in FY26: A strategic focus FY27+: A core growth driver for EBOS For personal use only portfolio Medical Technology Distribution: • Strong growth: across orthopaedics, • Additional OEM suppliers • Southeast Asia expansion: multi-co
Slide 39: Animal Care Driven by New Product Development
3D ANIMAL CARE TO BE DRIVEN BY ONGOING NEW PRODUCT DEVELOPMENT IN OUR CHAMPION BRANDS FY26: Embedding FY25: Volume growth FY27+: Building on the success For personal use only acquisitions Branded products & manufacturing: • Share gains for Black Hawk and • Product expansion through • Black Hawk & Vi
Slide 40: New Products Leading the Charge
3D NEW PRODUCTS LEADING THE CHARGE FY23 FY24 FY25 FY26 Continued evolution of life-stage driven portfolio with additional food options For personal use only Puppy Healthy benefits Mature Wet puppy High-meat Air/freeze dried treats Production extension in grocery channel Training and rewards Meat-bas
Slide 41: A Defensive Growth Care Business
A DEFENSIVE GROWTH CARE BUSINESS UNDERPINNED BY LONG-TERM INDUSTRY TRENDS, LEADING POSITIONS, GROWTH PIPELINE AND SHARED CAPABILITIES For personal use only Increased pharma and Stable Government Complex healthcare Pet Macro trends Ageing population medical spend funding needs Pet ownership humanisat
Slide 42: Business of Meeting
rsonal use only Business of Meeting
Slide 43: Annual Report and Financial Statements
ITEM 1 Annual Report and Financial Statements For personal use only To consider and receive the annual report and the financial statements for the year ended 30 June 2025 and the audit report thereon. 32
Slide 44: Election of Director – Coline McConville
ITEM 2 Resolution 1 – Election of Director – Coline McConville Coline McConville (BJuris, LLB, MBA (Harvard)) was appointed as a director by the Board to fill a casual vacancy effective 1 February For personal use only 2025. Ms McConville has over 20 years of governance experience across a wide rang
Slide 45: Re-election of Director – Stuart McLauchlan
ITEM 3 Resolution 2 – Re-election of Director – Stuart McLauchlan For personal use only Stuart McLauchlan (BCOM, FCA, CFInstD) was appointed to the EBOS Group Limited Board in July 2019 and was last re-elected by shareholders on 27 October 2022. He is Chairman of the Audit and Risk Committee and a m
Slide 46: Re-election of Director – Mark Bloom
ITEM 4 Resolution 3 – Re-election of Director – Mark Bloom For personal use only Mark Bloom (BCom, BAcc, CA) was appointed to the EBOS Group Limited Board in September 2022 and was last elected by shareholders on 27 October 2022. He is a member of the Audit and Risk Committee. He is currently a non-
Slide 47: Auditor's Remuneration
ITEM 5 Resolution 4 – Auditor’s remuneration For personal use only It is resolved that the directors of the Company be authorised to fix the fees and expenses of Deloitte as auditor of the Company. Deloitte is automatically reappointed as the auditor of the Company under section 207T of the Companie
Slide 48: Other Business
ITEM 6 To consider any other business that can be properly brought before the meeting. For personal use only 37
Slide 49: Conclusion
> A\uo 93s 1 Conclusion
Slide 50: For personal use only
For personal use only